We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 8 december 2017

The Lancet: [Articles] Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pool...

[Articles] Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Avelumab showed antitumour activity in the treatment of patients with platinum-refractory metastatic urothelial carcinoma; a manageable safety profile was reported in all avelumab-treated patients. These data provide the rationale for therapeutic use of avelumab in metastatic urothelial carcinoma and it has received accelerated US FDA approval in this setting on this basis.
Read more

[Articles] Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
The safety profile of buparlisib plus fulvestrant does not support its further development in this setting. Nonetheless, the efficacy of buparlisib supports the rationale for the use of PI3K inhibitors plus endocrine therapy in patients with PIK3CA mutations.
Read more

[News] Combined androgen blockade for salivary gland carcinoma
Combined androgen blockade with leuprorelin acetate and bicalutamide could be equally effective and less toxic than conventional chemotherapy for patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma, according to a recent study.
Read more

[Articles] Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Increased TIL concentration predicted response to neoadjuvant chemotherapy in all molecular subtypes assessed, and was also associated with a survival benefit in HER2-positive breast cancer and TNBC. By contrast, increased TILs were an adverse prognostic factor for survival in luminal–HER2-negative breast cancer, suggesting a different biology of the immunological infiltrate in this subtype. Our data support the hypothesis that breast cancer is immunogenic and might be targetable by immune-modulating therapies.
Read more

[News] BGJ398 for FGFR-altered advanced cholangiocarcinoma
Results from a single-arm, multicentre, phase 2 trial suggest that patients with advanced cholangiocarcinoma with genetic alterations in fibroblast growth factor receptor (FGFR) might respond to treatment with BGJ398, a first-in-class selective pan-FGFR kinase inhibitor.
Read more